Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.

CONCLUSIONS: The safety profile of RTS,S/AS01 in HIV-infected children was comparable to that of the comparator (meningococcal or rabies) vaccines. RTS,S/AS01 was immunogenic in HIV-infected children but antibody concentrations were lower than in children with an unknown or negative HIV status. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT00866619. PMID: 31708182 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31708182?dopt=Abstract

Source: Vaccine - November 6, 2019 Category: Allergy & Immunology Authors: Otieno L, Guerra Mendoza Y, Adjei S, Agbenyega T, Agnandji ST, Aide P, Akoo P, Ansong D, Asante KP, Berkley JA, Gesase S, Hamel MJ, Hoffman I, Kaali S, Kamthunzi P, Kariuki S, Kremsner P, Lanaspa M, Lell B, Lievens M, Lusingu J, Malabeja A, Masoud NS, Mto Tags: Vaccine Source Type: research